Richard B Colletti
Overview
Explore the profile of Richard B Colletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, et al.
Gastroenterology
. 2023 Apr;
165(1):149-161.e7.
PMID: 37004887
Background & Aims: Tumor necrosis factor inhibitors, including infliximab and adalimumab, are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of response are common. As combination therapy...
2.
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, et al.
J Pediatr Gastroenterol Nutr
. 2023 Feb;
76(5):566-575.
PMID: 36804501
Background: Biologic medications are recommended for treatment of moderately-to-severely active Crohn disease (CD) or ulcerative colitis (UC) in children. However, many patients require sequential biologic treatment because of nonresponse or...
3.
Zhang N, Liu C, Steiner S, Colletti R, Baldassano R, Chen S, et al.
J Comp Eff Res
. 2023 Feb;
12(4):e220136.
PMID: 36799351
To evaluate the performance of the multiple imputation (MI) method for estimating clinical effectiveness in pediatric Crohn's disease in the ImproveCareNow registry; to address the analytical challenge of missing data....
4.
Hunter T, Komocsar W, Liu C, Colletti R, Steiner S, Dotson J, et al.
Crohns Colitis 360
. 2023 Feb;
4(2):otac009.
PMID: 36777044
Background: To assess disease activity, steroid-free remission, and other clinical outcome assessments among pediatric patients with ulcerative colitis (UC) and Crohn's disease (CD) in the ImproveCareNow (ICN) registry. Methods: Patients...
5.
McNeish B, Colletti R, Hehir M
J Clin Neuromuscul Dis
. 2022 Nov;
24(2):113-114.
PMID: 36409346
No abstract available.
6.
Hunter T, Komocsar W, Colletti R, Liu C, Benkov K, Dotson J, et al.
Curr Med Res Opin
. 2022 Oct;
39(1):63-69.
PMID: 36263735
Objectives: To assess treatment patterns and initial and maintenance dosing of biologics over 3 years in pediatric patients with ulcerative colitis (UC) or Crohn's disease (CD), utilizing data from the...
7.
Adler J, Colletti R, Noonan L, Berzin T, Cheifetz A, Conklin L, et al.
Inflamm Bowel Dis
. 2022 Sep;
29(7):1089-1097.
PMID: 36049024
Background: To demonstrate treatment efficacy in Crohn's disease (CD), regulatory authorities require that trials include an endoscopic remission/response end point; however, standardized endoscopic assessment of disease activity, such as the...
8.
Adler J, Eder S, Gebremariam A, Moran C, Bass L, Moses J, et al.
Inflamm Bowel Dis
. 2021 Dec;
28(10):1537-1542.
PMID: 34964861
Background: Endoscopic mucosal healing is the gold standard for evaluating Crohn's disease (CD) treatment efficacy. Standard endoscopic indices are not routinely used in clinical practice, limiting the quality of retrospective...
9.
10.
Turner D, Carle A, Steiner S, Margolis P, Colletti R, Russell R, et al.
J Crohns Colitis
. 2017 Aug;
11(8):981-987.
PMID: 28789473
Background: The importance of a holistic approach with a comprehensive multidisciplinary team, including nutritional and psychosocial support, is becoming well recognised as a key contributor to optimal care in paediatric...